Document is current

Article History

Received: 1 December 2025

Accepted: 5 May 2026

First Online: 23 July 2026

Declarations

Competing interest: SM has received speaker honoraria from Menarini, Lilly and Sanofi. EGW has received personal fees from Abbott, AstraZeneca, Dexcom, Eli Lilly, Embecta, Insulet, Medtronic, Novo Nordisk, Roche, Sanofi, Sinocare, Tandem and Ypsomed and research support from Abbott, Embecta, Insulet, Novo Nordisk and Sanofi. KK has acted as a consultant, speaker or received grants for investigator-initiated studies for AstraZeneca, Abbott, Amgen, Bayer, Novartis, Novo Nordisk, Roche, Servier, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, NAPP, Pfizer, Roche, Servier, Boehringer Ingelheim, Daiichi-Sankyo, Embecta, Nestle Health Science, Oramed Pharmaceuticals and Applied Therapeutics. MJD has acted as a consultant/advisor and speaker for Eli Lilly, Novo Nordisk and Sanofi, has attended advisory boards for AbbVie, Amgen, AstraZeneca, Biomea Fusion, Carmot/Roche, Daewoong Pharmaceutical, Sanofi, Zealand Pharma, Regeneron, GSK and EktaH and acted as a speaker for AstraZeneca, Boehringer Ingelheim and Zuellig Pharma. MJD has received grants from AstraZeneca, Boehringer Ingelheim and Novo Nordisk. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.